{"id":"calcium-folinate-lv","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal toxicity (nausea, vomiting, diarrhea)"},{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcium folinate (leucovorin) acts as a cofactor that increases the cytotoxic effect of 5-FU chemotherapy by providing the necessary reduced folate cofactor for thymidylate synthase inhibition. This combination enhances DNA synthesis inhibition and improves the anti-tumor efficacy of 5-FU in colorectal cancer. It is commonly used as an adjunct to 5-FU-based chemotherapy regimens.","oneSentence":"Calcium folinate is a reduced form of folic acid that enhances the activity of fluorouracil (5-FU) by stabilizing the binding of fluorodeoxymonophosphate to thymidylate synthase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:45.072Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (adjuvant and metastatic, in combination with 5-fluorouracil)"}]},"trialDetails":[{"nctId":"NCT04083235","phase":"PHASE3","title":"A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-02-11","conditions":"Metastatic Adenocarcinoma of the Pancreas","enrollment":770},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT06360354","phase":"PHASE1","title":"A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-05-29","conditions":"Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers","enrollment":350},{"nctId":"NCT07363408","phase":"PHASE1","title":"Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-21","conditions":"Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8","enrollment":30},{"nctId":"NCT05026905","phase":"PHASE2","title":"A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Health Research Institutes, Taiwan","startDate":"2021-12-28","conditions":"Phase II, Open-label, Parallel 2-arm, Multi-center","enrollment":66},{"nctId":"NCT05030493","phase":"","title":"An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-08-31","conditions":"Colorectal Cancer","enrollment":787},{"nctId":"NCT07238283","phase":"PHASE3","title":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-02","conditions":"First-line Treatment of Metastatic Pancreatic Cancer","enrollment":662},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT05945901","phase":"PHASE2, PHASE3","title":"A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-08-14","conditions":"Colorectal Cancer","enrollment":669},{"nctId":"NCT07099794","phase":"PHASE2","title":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":90},{"nctId":"NCT07085273","phase":"PHASE2","title":"Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-08-15","conditions":"Gastric Cancer","enrollment":33},{"nctId":"NCT06993025","phase":"PHASE2","title":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":30},{"nctId":"NCT02138617","phase":"PHASE2","title":"Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05-06","conditions":"Colon Cancer","enrollment":100},{"nctId":"NCT02394834","phase":"","title":"An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":757},{"nctId":"NCT04796948","phase":"PHASE1","title":"A Study of Irinotecan Liposome in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-08","conditions":"Advanced Pancreatic Cancer","enrollment":41},{"nctId":"NCT00059930","phase":"PHASE1","title":"Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":38},{"nctId":"NCT01814501","phase":"PHASE2","title":"Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab","status":"COMPLETED","sponsor":"John Hays","startDate":"2013-02-01","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":16},{"nctId":"NCT06184698","phase":"PHASE2","title":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":173},{"nctId":"NCT06475326","phase":"PHASE2","title":"Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-06-05","conditions":"Pancreatic Cancer","enrollment":87},{"nctId":"NCT06501664","phase":"PHASE3","title":"Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC","status":"NOT_YET_RECRUITING","sponsor":"Rui-hua Xu, MD, PhD","startDate":"2024-08-01","conditions":"Esophageal Cancer","enrollment":360},{"nctId":"NCT06387810","phase":"PHASE2","title":"Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-17","conditions":"Borderline Resectable Pancreatic Cancer","enrollment":45},{"nctId":"NCT05751850","phase":"PHASE3","title":"HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-06-13","conditions":"First-line Treatment of Advanced Pancreatic Cancer","enrollment":778},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT06383078","phase":"PHASE2","title":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-20","conditions":"Efficacy and Safety","enrollment":120},{"nctId":"NCT06363552","phase":"PHASE2","title":"A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianshu Liu","startDate":"2024-05","conditions":"Metastatic Colorectal Cancer","enrollment":36},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT06217042","phase":"PHASE3","title":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-02-05","conditions":"Pancreatic Cancer","enrollment":524},{"nctId":"NCT02037048","phase":"PHASE2","title":"FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma","status":"UNKNOWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-02-10","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia","enrollment":63},{"nctId":"NCT06172036","phase":"PHASE2","title":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2024-01-20","conditions":"Neoadjuvant Chemotherapy, Resectable Pancreatic Cancer","enrollment":180},{"nctId":"NCT02394795","phase":"PHASE3","title":"Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-05-29","conditions":"Colorectal Cancer","enrollment":823},{"nctId":"NCT01068327","phase":"PHASE1","title":"Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2007-11-05","conditions":"Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer","enrollment":46},{"nctId":"NCT00601198","phase":"PHASE2","title":"A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"University of Cincinnati","startDate":"2006-10","conditions":"Colorectal Cancer","enrollment":4},{"nctId":"NCT01835041","phase":"PHASE1","title":"CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-04","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":21},{"nctId":"NCT00003298","phase":"PHASE2","title":"Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-06-01","conditions":"Gastric Cancer","enrollment":39},{"nctId":"NCT00303628","phase":"PHASE3","title":"Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2006-05-11","conditions":"Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer","enrollment":355},{"nctId":"NCT00098787","phase":"PHASE2","title":"Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-09-08","conditions":"Colorectal Cancer","enrollment":247},{"nctId":"NCT00002525","phase":"PHASE3","title":"Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1993-10-01","conditions":"Colorectal Cancer","enrollment":859},{"nctId":"NCT02344810","phase":"PHASE1, PHASE2","title":"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"2015-03-06","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach","enrollment":""},{"nctId":"NCT01212822","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2011-04-27","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach","enrollment":20},{"nctId":"NCT01871571","phase":"PHASE2","title":"Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2013-08-02","conditions":"Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer","enrollment":17},{"nctId":"NCT02293109","phase":"PHASE1","title":"Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Mehrdad Abedi, MD","startDate":"2015-12-17","conditions":"Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma","enrollment":10},{"nctId":"NCT02015819","phase":"PHASE1","title":"Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2014-10-07","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":16},{"nctId":"NCT01666730","phase":"PHASE2","title":"Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2013-02-21","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":50},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT00628810","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2007-01","conditions":"Colorectal Cancer","enrollment":86},{"nctId":"NCT02497157","phase":"PHASE2","title":"Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2015-05-21","conditions":"Metastatic Colorectal Cancer","enrollment":45},{"nctId":"NCT00079274","phase":"PHASE3","title":"Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02","conditions":"Adenocarcinoma of the Colon, Stage III Colon Cancer","enrollment":3397},{"nctId":"NCT01643499","phase":"PHASE1","title":"Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2012-03-26","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary","enrollment":79},{"nctId":"NCT04097444","phase":"PHASE2","title":"CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC","status":"UNKNOWN","sponsor":"Chugai Pharmaceutical","startDate":"2019-10-11","conditions":"Metastatic Colorectal Cancer","enrollment":112},{"nctId":"NCT01964755","phase":"PHASE2","title":"Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2009-04-21","conditions":"Epstein Barr Virus Associated Non Hodgkin's Lymphoma, Epstein Barr Virus Associated Hodgkin's Lymphoma, Post-Transplant Lymphoproliferative Disease","enrollment":6},{"nctId":"NCT02337946","phase":"PHASE2","title":"Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-10-16","conditions":"Colorectal Carcinoma","enrollment":164},{"nctId":"NCT00068692","phase":"PHASE3","title":"Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-10-15","conditions":"Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma","enrollment":225},{"nctId":"NCT02041481","phase":"PHASE1","title":"MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2014-06","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":26},{"nctId":"NCT00098839","phase":"PHASE1, PHASE2","title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-02","conditions":"Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":134},{"nctId":"NCT01279681","phase":"PHASE3","title":"Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2011-01","conditions":"Cognitive/Functional Effects, Colorectal Cancer, Neurotoxicity","enrollment":32},{"nctId":"NCT02246049","phase":"PHASE2","title":"A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2014-05","conditions":"Colorectal Neoplasms","enrollment":69},{"nctId":"NCT01231399","phase":"PHASE1, PHASE2","title":"Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2012-02","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach","enrollment":6},{"nctId":"NCT00610948","phase":"PHASE1","title":"Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2008-03","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":74},{"nctId":"NCT01229111","phase":"PHASE2","title":"Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10","conditions":"Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct","enrollment":14},{"nctId":"NCT00873093","phase":"PHASE2","title":"Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-03","conditions":"B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia","enrollment":148},{"nctId":"NCT02935764","phase":"PHASE3","title":"FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-10","conditions":"Colorectal Carcinoma","enrollment":164},{"nctId":"NCT01320683","phase":"PHASE2","title":"Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2011-03","conditions":"Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer","enrollment":1},{"nctId":"NCT00002716","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1996-01","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":135},{"nctId":"NCT00296608","phase":"PHASE3","title":"Radiation Therapy With or Without Chemotherapy Before Surgery in Treating Patients With Stage II or Stage III Rectal Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"1993-04","conditions":"Colorectal Cancer","enrollment":762},{"nctId":"NCT00982592","phase":"PHASE2","title":"Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer","enrollment":124},{"nctId":"NCT01670084","phase":"PHASE2","title":"Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2012-12","conditions":"B-cell Adult Acute Lymphoblastic Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":""},{"nctId":"NCT00100841","phase":"PHASE2","title":"Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11","conditions":"Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer","enrollment":66},{"nctId":"NCT01205022","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-04","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer","enrollment":3},{"nctId":"NCT01238965","phase":"PHASE1","title":"Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2010-10","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer","enrollment":7},{"nctId":"NCT02235324","phase":"PHASE2","title":"Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2015-03","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":""},{"nctId":"NCT00262925","phase":"PHASE2","title":"Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06","conditions":"Recurrent Adult Acute Lymphoblastic Leukemia","enrollment":12},{"nctId":"NCT02376452","phase":"PHASE2","title":"Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2014-09","conditions":"Colorectal Carcinoma","enrollment":100},{"nctId":"NCT00039377","phase":"PHASE2","title":"Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-04","conditions":"Adult Acute Lymphoblastic Leukemia in Remission","enrollment":58},{"nctId":"NCT00057811","phase":"PHASE2","title":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-06","conditions":"Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma","enrollment":97},{"nctId":"NCT00499369","phase":"PHASE3","title":"Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-06","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":72},{"nctId":"NCT01941173","phase":"NA","title":"Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2014-01","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer","enrollment":""},{"nctId":"NCT01198548","phase":"PHASE2","title":"High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2010-08","conditions":"Stage IV Colon Cancer, Stage IV Rectal Cancer","enrollment":10},{"nctId":"NCT00942266","phase":"PHASE2","title":"Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2009-07","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":58},{"nctId":"NCT00323011","phase":"PHASE2","title":"FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2006-05","conditions":"Colorectal Cancer","enrollment":5},{"nctId":"NCT00022737","phase":"PHASE3","title":"Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT00008281","phase":"PHASE3","title":"Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sanofi","startDate":"2000-10","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00080990","phase":"PHASE1","title":"Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-02","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":46},{"nctId":"NCT00007878","phase":"PHASE1","title":"Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-09","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":30},{"nctId":"NCT00043121","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-06","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":50},{"nctId":"NCT00021073","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-05","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":90},{"nctId":"NCT00003835","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Stage III Colon Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-05","conditions":"Adenocarcinoma of the Colon, Stage III Colon Cancer","enrollment":1260},{"nctId":"NCT00138177","phase":"PHASE1","title":"Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-07","conditions":"Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer","enrollment":54},{"nctId":"NCT00060411","phase":"PHASE1","title":"A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-06","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":24},{"nctId":"NCT00016198","phase":"PHASE2","title":"Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Prologue Research International","startDate":"2001-05","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00006786","phase":"PHASE2","title":"Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2000-11","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00098982","phase":"PHASE1","title":"Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2004-09","conditions":"Colorectal Cancer","enrollment":16},{"nctId":"NCT00042874","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-05","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":77},{"nctId":"NCT00025142","phase":"PHASE2","title":"Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2001-07","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT00281944","phase":"PHASE1","title":"Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09","conditions":"Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor","enrollment":42},{"nctId":"NCT00005036","phase":"PHASE3","title":"Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1999-11","conditions":"Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":560},{"nctId":"NCT00002551","phase":"PHASE3","title":"SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1994-03","conditions":"Colorectal Cancer","enrollment":1917},{"nctId":"NCT00003956","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1999-04","conditions":"Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":25},{"nctId":"NCT00023998","phase":"PHASE2","title":"Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-07","conditions":"Metastatic Osteosarcoma","enrollment":80},{"nctId":"NCT00070122","phase":"PHASE3","title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-04","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":2200},{"nctId":"NCT00025337","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-09","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":880}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1565,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LV"],"phase":"phase_3","status":"active","brandName":"Calcium folinate (LV)","genericName":"Calcium folinate (LV)","companyName":"Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group","companyId":"multicenter-clinical-study-group-of-osaka-colorectal-cancer-treatment-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcium folinate (LV) is a small molecule used in the treatment of various cancers, including colorectal, gastrointestinal, biliary tract, and pancreatic cancers, as well as recurrent childhood acute lymphoblastic leukemia. The exact mechanism of action of calcium folinate is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}